Atlas Trials

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

Clinical trial NCT02308670 · COMPLETED

Trial details

NCT number
NCT02308670
Sponsor
University at Buffalo
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Sclerosis
Start date
2014-07-01
Primary completion
2016-10-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.